Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Ozurdex

This page shows the latest Ozurdex news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer's Eylea in diabetic eye condition

NICE backs Bayer's Eylea in diabetic eye condition

NICE backs Bayer's Eylea in diabetic eye condition. TheInstitute also recommends Allergan's Ozurdex in final guidance. ... Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema (DMO).

Latest news

  • NICE recommends Ozurdex for diabetic eye condition NICE recommends Ozurdex for diabetic eye condition

    NICE recommends Ozurdex for diabetic eye condition. Draft guidance cites implant as option for patients with diabetic macular oedema. ... Ozurdex is injected into the eye once every six months and works by suppressing inflammation and preventing oedema

  • Fresh approval for Roche's Lucentis as competition heats up Fresh approval for Roche's Lucentis as competition heats up

    Roche's drug is being challenged in the market by Bayer's Eylea (aflibercept) as well as newer entrants such as Allergan's Ozurdex (intravitreal dexamethasone).

  • New eye indication for Allergan’s Ozurdex New eye indication for Allergan’s Ozurdex

    New eye indication for Allergan’ s Ozurdex. EU approval extends the drug's use to diabetic macular oedema. ... Ozurdex joins a competitive market for DMO, with approved drugs in the EU including Novartis' Lucentis (ranibizumab).

  • Allergan will start phase III DARPin trials next year Allergan will start phase III DARPin trials next year

    On the plus side, Allergan said the FDA had approved a new indication for its intravitreal implant Ozurdex (dexamethasone), namely the treatment of diabetic macular oedema (DME) in adults who have

  • NICE against new indication for Novartis' Lucentis

    Its draft guidance concluded the ICER for Lucentis in central RVO versus Allergan's Ozurdex (dexamethasone) intravitreal implant, the currently approved treatment, was likely to be over £37, 400 per QALY ... Ozurdex was recommended by NICE earlier this

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Quick links

Infographics

Multimedia